Skip to main content
ITRMF logo

ITRMF · Iterum Therapeutics plc

$0.03 +0.00 (+0.00%) At close · Jul 23
Market Cap
$1.38M
Shares
44.66M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$0
FY2021 Revenue FY2018–FY2021
Net Income
-$24.77M +35.4%
FY2024 Net Income FY2018–FY2024
Operating Margin
-275732.43% -266922.4pp
FY2019 Operating Margin FY2018–FY2019
Diluted EPS
-$1.26 +57.4%
FY2024 Diluted EPS FY2022–FY2024
Operating Cash Flow
-$26.77M +31.9%
FY2024 Operating Cash Flow FY2018–FY2024

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
$0 $0 $37K $869K
$4.15M $10.46M $39.99M $17.62M $10.71M $21.07M $90.77M $68.65M
$10.86M $7.98M $7.48M $12.77M $13.83M $11.05M $11.28M $8.78M
$254K $1.72M $1.72M $1.71M
$21.03M $18.7M $47.47M $30.38M $24.54M $32.13M $102.06M $77.43M
-$20.64M -$18.7M -$47.47M -$30.38M -$24.54M -$32.13M -$102.02M -$76.56M
-275732.43% -8810.01%
$2.75M $3.31M
$588K $789K
-$6.05M -$5.84M $9.71M -$13.75M -$66.32M -$19.14M -$665K -$25K
$125K $125K $125K $423K
-$26.69M -$24.53M -$37.76M -$44.13M -$90.86M -$51.26M -$102.69M -$76.58M
$276K $240K $613K $301K $705K $743K $444K $472K
-$26.96M -$24.77M -$38.37M -$44.43M -$91.56M -$52.01M -$103.13M -$77.06M
-278729.73% -8867.2%
-$26.96M -$24.78M -$38.02M -$44.78M
USD/shares -$1.26 -$2.96 -$3.63
USD/shares -$1.26 -$2.96 -$3.63
shares 19.7M 12.96M 12.24M 10.89M 1.6M 967.87K 582.27K
shares 19.7M 12.96M 12.24M 10.89M 1.6M 967.87K 582.27K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation over time computed as of each quarter's filing date

Key facts CIK 1659323 CUSIP G6333L200 13F (30d) 2 filings 1 filers Visit website Investor relations